BG105736A - 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors - Google Patents
2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitorsInfo
- Publication number
- BG105736A BG105736A BG105736A BG10573601A BG105736A BG 105736 A BG105736 A BG 105736A BG 105736 A BG105736 A BG 105736A BG 10573601 A BG10573601 A BG 10573601A BG 105736 A BG105736 A BG 105736A
- Authority
- BG
- Bulgaria
- Prior art keywords
- matrix metalloproteinase
- benzodiasepine
- tetrahydro
- hydroxamic acid
- metalloproteinase inhibitors
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- -1 tumor growth Chemical compound 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908099A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001991 WO2000044730A1 (en) | 1999-01-27 | 2000-01-27 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105736A true BG105736A (en) | 2002-05-31 |
Family
ID=22900512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105736A BG105736A (en) | 1999-01-27 | 2001-07-26 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1147095B1 (cs) |
| JP (1) | JP2002535392A (cs) |
| KR (1) | KR20010101730A (cs) |
| CN (1) | CN1197849C (cs) |
| AR (1) | AR022423A1 (cs) |
| AT (1) | ATE273288T1 (cs) |
| AU (1) | AU767039B2 (cs) |
| BG (1) | BG105736A (cs) |
| BR (1) | BR0007759A (cs) |
| CA (1) | CA2356267A1 (cs) |
| CZ (1) | CZ20012637A3 (cs) |
| DE (1) | DE60012883T2 (cs) |
| EA (1) | EA200100809A1 (cs) |
| ES (1) | ES2223470T3 (cs) |
| HU (1) | HUP0105302A3 (cs) |
| ID (1) | ID29046A (cs) |
| IL (1) | IL144168A0 (cs) |
| NO (1) | NO20013675L (cs) |
| NZ (1) | NZ511885A (cs) |
| PL (1) | PL349025A1 (cs) |
| PT (1) | PT1147095E (cs) |
| SK (1) | SK10422001A3 (cs) |
| TR (1) | TR200102131T2 (cs) |
| WO (1) | WO2000044730A1 (cs) |
| ZA (1) | ZA200104321B (cs) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| AU2002324716A1 (en) | 2001-08-17 | 2003-03-03 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| WO2003037852A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
| CA2494014A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
| ATE520935T1 (de) | 2003-05-21 | 2011-09-15 | Alexza Pharmaceuticals Inc | Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| DE602005023874D1 (de) | 2004-07-21 | 2010-11-11 | Merck Serono Sa | Octahydropyrroloä2, 3, cüpyridinderivative und pharmazeutische verwendung damit |
| WO2006022714A1 (en) | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| WO2007141029A1 (en) * | 2006-06-08 | 2007-12-13 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Specific protease inhibitors and their use in cancer therapy |
| WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| ES2592154T3 (es) | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
| RU2578607C2 (ru) | 2010-09-17 | 2016-03-27 | Дзе Юниверсити Оф Токио | Композиция для поддержания функции тромбоцитов |
| EP3746138A4 (en) | 2018-02-02 | 2021-11-03 | Alexza Pharmaceuticals, Inc. | ELECTRIC CONDENSING AEROSOL DEVICE |
| JP2022512584A (ja) | 2018-10-04 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 角皮症を処置するためのｅｇｆｒインヒビター |
| WO2021055817A1 (en) * | 2019-09-19 | 2021-03-25 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| DE69519751T2 (de) * | 1995-04-20 | 2001-04-19 | Pfizer Inc., New York | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
| CN1131215C (zh) * | 1995-11-13 | 2003-12-17 | 赫彻斯特股份公司 | 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸 |
| US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| AU725831C (en) * | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| CN1228773A (zh) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 杂环金属蛋白酶抑制剂 |
| EP0927168B1 (en) * | 1996-08-28 | 2002-11-06 | The Procter & Gamble Company | 1,3-diheterocyclic metalloprotease inhibitors |
| DK0923561T3 (da) * | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
| JP2002501056A (ja) * | 1998-01-27 | 2002-01-15 | アメリカン・サイアナミド・カンパニー | マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸 |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Withdrawn
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID29046A (id) | 2001-07-26 |
| CZ20012637A3 (cs) | 2002-04-17 |
| AU767039B2 (en) | 2003-10-30 |
| ZA200104321B (en) | 2002-08-26 |
| JP2002535392A (ja) | 2002-10-22 |
| AU3216000A (en) | 2000-08-18 |
| TR200102131T2 (tr) | 2001-12-21 |
| NO20013675D0 (no) | 2001-07-26 |
| NZ511885A (en) | 2003-06-30 |
| PL349025A1 (en) | 2002-07-01 |
| AR022423A1 (es) | 2002-09-04 |
| BR0007759A (pt) | 2001-11-13 |
| HUP0105302A3 (en) | 2002-09-30 |
| DE60012883D1 (de) | 2004-09-16 |
| DE60012883T2 (de) | 2005-08-25 |
| NO20013675L (no) | 2001-09-21 |
| ES2223470T3 (es) | 2005-03-01 |
| CN1337952A (zh) | 2002-02-27 |
| CN1197849C (zh) | 2005-04-20 |
| EP1147095B1 (en) | 2004-08-11 |
| PT1147095E (pt) | 2004-12-31 |
| SK10422001A3 (sk) | 2002-09-10 |
| ATE273288T1 (de) | 2004-08-15 |
| CA2356267A1 (en) | 2000-08-03 |
| HUP0105302A2 (hu) | 2002-07-29 |
| WO2000044730A1 (en) | 2000-08-03 |
| EP1147095A1 (en) | 2001-10-24 |
| EA200100809A1 (ru) | 2002-02-28 |
| IL144168A0 (en) | 2002-05-23 |
| KR20010101730A (ko) | 2001-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105736A (en) | 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | |
| TR200102967T2 (tr) | Substitüsyonlu azollar | |
| WO1996040745A3 (en) | Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases | |
| GC0000221A (en) | Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them | |
| UA72910C2 (uk) | АЦЕТИЛЕНОВІ, ОСНОВАНІ НА <font face="Symbol">a</font>-АМІНОКИСЛОТАХ, ПОХІДНІ СУЛЬФОНАМІДІВ ГІДРОКСАМОВИХ КИСЛОТ, ЯКІ ІНГІБУЮТЬ TACE, СПОСІБ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ), ПРОМІЖНА СПОЛУКА (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПАТОЛОГІЧНИХ ЗМІН, ПОВ'ЯЗАНИХ З УЧАСТЮ ТАСЕ, І ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ | |
| PT2261335T (pt) | Composições e métodos para aumentar a mineralização óssea | |
| MXPA04000622A (es) | Pirazolilcarboxanilidas como funguicidas. | |
| BG105650A (en) | Azepinoindole derivatives, the production and use thereof | |
| GR3029449T3 (en) | (e)-20(22)-dehydrovitamin d compounds | |
| DE69912479D1 (de) | 4- und 5-alkynyloxindole sowie 4- und 5-alkenyloxindole | |
| AU6276700A (en) | Liquid-crystalline medium | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| EP1077218A3 (en) | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | |
| TR28332A (tr) | Arilasetik asit türevleri. | |
| ATE280152T1 (de) | Acetylenische sulfonamid-thiol-tace-inhibitoren | |
| ATE288922T1 (de) | Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen | |
| GB2324528A (en) | Cytostatic hydroxamic acid derivatives | |
| GB9923710D0 (en) | Chemical compounds | |
| PT1144369E (pt) | Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace | |
| EA200100808A1 (ru) | ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE | |
| ID27440A (id) | Proses untuk menyiapkan penengah-penengah | |
| AU2002322396A1 (en) | 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists | |
| BR0007726A (pt) | Composto, processo para preparar o mesmo,método de inibir mudanças patológicas, e,composição farmacêutica. | |
| HUT56550A (en) | Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds | |
| BG105618A (en) | Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists |